Physician profile
Melvyn Ranish
NPI 1326048240
$1,166.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.62 · 2020: $82.27 · 2021: $433 · 2022: $596.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $236.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $178.17 | 2022 | |
| Glaxosmithkline, LLC. | $103.29 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $97.88 | 2019-2022 | |
| Abbvie INC. | $93.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.33 | 2020-2022 | |
| Csl Behring | $76.74 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $62.13 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $51.50 | 2021 | |
| Eyevance Pharmaceuticals LLC | $46.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.05 | 2022 | |
| Genentech USA, INC. | $34.71 | 2021 | |
| Kaleo, INC. | $28.56 | 2019-2022 | |
| Uswm, LLC | $17.00 | 2021 | |
| Pfizer INC. | $14.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvyn Ranish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.